RIGL
Rigel Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$564.75M
P/E Ratio
1.57
EPS
$19.48
Beta
1.27
52W High
$52.24
52W Low
$16.88
50-Day MA
$29.98
200-Day MA
$34.01
Dividend Yield
—
Profit Margin
124.70%
Forward P/E
6.45
PEG Ratio
-0.10
About Rigel Pharmaceuticals Inc
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases. The company is headquartered in South San Francisco, California.
Fundamentals
| Revenue (TTM) | $294.28M |
| Gross Profit (TTM) | $241.37M |
| EBITDA | $127.88M |
| Operating Margin | 33.20% |
| Return on Equity | 185.90% |
| Return on Assets | 23.20% |
| Revenue/Share (TTM) | $16.36 |
| Book Value | $21.38 |
| Price-to-Book | 1.44 |
| Price-to-Sales (TTM) | 1.92 |
| EV/Revenue | 1.571 |
| EV/EBITDA | 3.51 |
| Quarterly Earnings Growth (YoY) | 1599.00% |
| Quarterly Revenue Growth (YoY) | 21.20% |
| Shares Outstanding | $18.48M |
| Float | $18.17M |
| % Insiders | 3.07% |
| % Institutions | 90.45% |
Historical Volatility
HV 10-Day
38.82%
HV 20-Day
45.62%
HV 30-Day
43.01%
HV 60-Day
46.73%
HV Rank
13.5%
Volatility is currently contracting
Analyst Ratings
Consensus ($51.20 target)
3
Buy2
HoldData last updated: 4/29/2026